Filing Flows › PTC Therapeutics (PTCT) › Royalty revenue revenue
PTC Therapeutics (PTCT) Royalty revenue revenue by quarter
PTC Therapeutics' Royalty revenue revenue was $81.7M in Q3 2026 (third quarter 2026), +15% from Q2 2026. Over the last 6 quarters it ranged from $36.4M (Q1 2025) to $81.7M (Q3 2026).
| Quarter | Royalty revenue revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $81.7M | +15% | +15% |
| Q2 2026 | $71.1M | +52% | +23% |
| Q1 2026 | $46.8M | -34% | +29% |
| Q3 2025 | $70.8M | +23% | — |
| Q2 2025 | $57.6M | +58% | — |
| Q1 2025 | $36.4M | — | — |
Q3 2026 at a glance
PTC Therapeutics, Q3 2026: revenue $358M (+70% year over year), operating margin 7.0%, net loss $51.7M, operating cash flow −$25.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is PTC Therapeutics' Royalty revenue revenue?
PTC Therapeutics' Royalty revenue revenue was $81.7M in Q3 2026 (third quarter 2026), +15% from Q2 2026.
How has PTC Therapeutics' Royalty revenue revenue changed?
Over the last 6 quarters it ranged from $36.4M (Q1 2025) to $81.7M (Q3 2026).